Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2014 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2014 Financial Results and Provides Corporate Update −Quarterly Conference Call Today at 8:00 am ET−
Wholly owned product candidates - advancing, with expanding news flow expected. Kadcyla ® sales growing - launches in European Union starting. Beyond Kadcyla - encouraging initial clinical findings now reported with six other compounds in development through partnerships.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be
View HTML
Toggle Summary ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming 50th Annual Meeting of ASCO
Abstracts made public today provide insight on biological effects seen at low doses with IMGN529 and on observed activity threshold for IMGN853. Abstracts also add to growing body of data on the significance of partner compounds, including the findings reported on the activity and tolerability of
View HTML
Toggle Summary ImmunoGen, Inc. Announces Favorable STARLYTE Phase II Clinical Data with Sanofi's SAR3419 in Diffuse Large B-Cell Lymphoma
SAR3419 achieved objective responses well above the study threshold and was found to have a favorable safety profile. Objective responses reported in patients whose disease had not responded to prior therapy. Selected for Best of ASCO. WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Preclinical Findings for IMGN779, a Potential Treatment for Acute Myeloid Leukemia
  Novel antibody-drug conjugate is designed to selectively target and kill CD33-expressing acute myeloid leukemia cells, including leukemic stem cells, while sparing normal cells. IMGN779 utilizes one of the Company's new DNA-acting payload agents, DGN462.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2014 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2014 Financial Results
−Company Provides Corporate Update and Fiscal Year 2015 Financial Guidance − − Conference Call Today at 8:00 am ET− Advancing pipeline of wholly owned therapeutic candidates: IMGN853 beginning evaluation in target patient populations; initial evidence of IMGN529 activity reported; IMGN289 being
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentation by Company management at an upcoming investor conference will be
View HTML
Toggle Summary ImmunoGen, Inc. Announces Morgan Stanley Global Healthcare Conference Webcast
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will participate in the Morgan Stanley Global Healthcare Conference .
View HTML